{"nctId":"NCT02791516","briefTitle":"A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis","startDateStruct":{"date":"2017-01-16","type":"ACTUAL"},"conditions":["Postmenopausal Osteoporosis"],"count":67,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Romosozumab","type":"EXPERIMENTAL","interventionNames":["Drug: Romosozumab"]}],"interventions":[{"name":"Romosozumab","otherNames":["AMG 785","Evenity"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ambulatory postmenopausal Korean women, ≥ 55 to ≤ 90 years of age at enrollment.\n* Postmenopause is defined as no spontaneous vaginal bleeding or spotting for 12 or more consecutive months prior to screening.\n* BMD T-score \\</= -2.50 at the lumbar spine, total hip or femoral neck.\n* At least 2 vertebrae in the L1 through L4 region and at least one hip are evaluable by DXA.\n* Other inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Subjects with a BMD T-score \\</= -4.0 at the lumbar spine, total hip, or femoral neck.\n* History of hip fracture.\n* Bone disease other than osteoporosis/ or evidence of any other clinically significant disorder, condition/ or disease or significant laboratory abnormalities.\n* Known sensitivity or intolerance calcium and vitamin D products.\n* Other exclusion criteria may apply.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"55 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline to Month 6 in Bone Mineral Density at the Lumbar Spine","description":"Bone mineral density (BMD) at the lumbar spine was assessed by dual-energy x-ray absorptiometry (DXA). Images were assessed by a central reader.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.8"},{"groupId":"OG001","value":"9.5","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Month 6 in Bone Mineral Density at the Total Hip","description":"Bone mineral density (BMD) at the total hip was assessed by dual-energy x-ray absorptiometry (DXA). Images were assessed by a central reader.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.4"},{"groupId":"OG001","value":"2.9","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Month 6 in Bone Mineral Density at the Femoral Neck","description":"Bone mineral density (BMD) at the femoral neck was assessed by dual-energy x-ray absorptiometry (DXA). Images were assessed by a central reader.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.7"},{"groupId":"OG001","value":"3.0","spread":"0.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":33},"commonTop":["Nasopharyngitis","Back pain"]}}}